The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Tislelizumab is now approved in nine indications in China
Based on a post hoc analysis, fewer required respiratory interventions
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
